In this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can identify recurrence months earlier than conventional methods, allowing for timely intervention and more informed decision-making. As a result, MRD testing is becoming an increasingly valuable tool in personalized cancer care.

In this episode of OncoTalks, Dr. Ira Zackon, Senior Medical Director at Ontada, is joined by Dr. Marcus Neubauer, Medical Director for Professional Wellbeing at The US Oncology Network, to explore the pressing issue of provider burnout in healthcare. Together, they examine the root causes, personal and organizational impacts, and the importance of fostering a culture where provider well-being is not only supported, but expected.

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liquid biopsy testing.

Introducing a new and exciting video podcast experience: OncoTalks Case Journey. Tune into our debut episode as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer. 

In this episode of OncoTalks, Dr. Paul Conkling and Dr. David Cosgrove explore the latest advancements in mCRC treatment, highlighting the shift from traditional chemotherapy to innovative targeted therapies driven by genomic insights. We discuss the role of next-generation sequencing, new therapeutic agents, and clinical trials, while emphasizing personalized care, addressing treatment challenges, side effects, and financial considerations, offering a hopeful outlook on improved survival rates and future therapies with reduced toxicity.

Join us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategies to enhance patient outcomes.

Join us as we explore the transformative potential of HER2 testing in breast cancer care. In this episode of OncoTalks, Dr. Paul Conkling and Dr. Erika Hamilton share cutting-edge insights that every oncologist should know to stay at the forefront of breast cancer treatment. Tune in to discover how HER2 testing is reshaping the landscape of personalized cancer therapy.

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies.

Join Dr. Paul Conkling and Dr. Akash Mukherjee as they explore CAR-T Therapy from design of treatment through the patient journey.

Join Dr. Ira Zackon and Dr. David Andorsky on today’s episode of OncoTalks, as they discuss the expanding role of bispecific antibody therapies in the community for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL).